Soligenix (SNGX) Q3 2026 earnings summary

Executive summary

• Net loss narrowed in Q3 and 9M 2026 as R&D spending fell after the HyBryte development program was terminated; a vendor-liability settlement gain also reduced losses.

• Development focus includes SGX302 for psoriasis, SGX945 for Behçet's disease, SGX942 for oral mucositis, and government-funded vaccine programs.

Financial highlights

• Revenue was $0 for Q3 and 9M 2026 and the comparable 2025 periods.

• Q3 2026 net loss was $1.12M vs. $2.53M in Q3 2025; 9M net loss was $5.93M vs. $8.18M.

• R&D expense fell to $357K in Q3 2026 from $1.58M and to $3.11M for 9M from $5.20M; G&A was $1.02M and $3.25M, respectively.

• Q3 and 9M 2026 included gains on extinguishment of vendor liabilities of $180K and $238K, respectively.

Outlook and guidance

• Cash runway is expected to support operations, development and obligations into Q2 2028, based on the current budget, cash outflows and cash on hand.

• Planned R&D spending for the next 12 months is $1.6M, with the substantial majority allocated to Specialized BioTherapeutics; no grant reimbursements are anticipated to offset that segment's R&D.

• Priorities include advancing SGX302 and SGX945, seeking a partner for SGX942's next Phase 3 study, and pursuing government grants, partnerships and strategic alternatives.